For decades, Varex has pioneered the development of X-ray sources and digital X-ray detectors, and also provides high-voltage interconnects and imaging software to global OEM manufacturers.  Varex’s X-ray tubes, flat panel and photon counting detectors, and connect and control accessories are used in medical diagnostic imaging, non-destructive inspection, security and vehicle inspection systems, and analysis and measurement applications.

“Teledyne entered the healthcare market with the acquisition of Teledyne DALSA in 2011, which was beginning to develop low-dose, high-resolution CMOS-based X-ray detectors.  Nearly ten years ago, we expanded our presence with the acquisition of Teledyne e2v in 2017, a long-term supplier of magnetrons to cancer radiotherapy OEMs. Nevertheless, while Teledyne and Varex serve similar customers with related technologies, our products are uniquely complementary with minimal overlap,” said Robert Mehrabian, Executive Chairman of Teledyne.  “For example, while Teledyne produces X-ray detectors, we do not provide detectors suited for high-radiation environments such as oncology, as does Varex.  In addition, only Varex provides new advanced photon counting detectors for healthcare and industrial inspection.  Finally, while Teledyne produces various vacuum electronics, like magnetrons, we have never produced X-ray tubes for radiography, fluoroscopy or computed tomography applications.”

Sunny Sanyal, President, Chief Executive Officer and Director of Varex, commented, “Joining Teledyne marks an exciting new chapter for Varex. This transaction provides a substantial premium for our shareholders and exciting opportunities for our customers and employees across the medical and industrial markets we serve. Our X-ray technologies fit naturally alongside Teledyne’s product portfolio, and its resources will help us accelerate adoption of our advanced imaging solutions, and development of the next generation of products.”

This transaction is anticipated to be completed in early 2027 and is subject to customary closing conditions, including regulatory approvals and Varex’s stockholder approval.

Evercore is acting as exclusive financial advisor and Orrick, Herrington & Sutcliffe LLP is acting as legal counsel to Varex. Latham & Watkins LLP and McGuireWoods LLP are acting as legal counsel to Teledyne.

About Teledyne

Teledyne Technologies is a leading provider of sophisticated digital imaging products and software, instrumentation, aerospace and defense electronics, and engineered systems. Teledyne’s operations are primarily located in the United States, the United Kingdom, Canada, and Western and Northern Europe. For more information, visit Teledyne’s website at www.teledyne.com.

About Varex

Varex Imaging Corporation is a leading innovator, designer, and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors, and other image processing solutions that are key components of X-ray imaging systems, as well as X-ray imaging systems for industrial applications. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,500 people located in North America, Europe, and Asia. For more information, visit vareximaging.com.

Additional Information About the Acquisition and Where to Find It

In connection with the proposed transaction (the “Transaction”), Varex will file with the Securities and Exchange Commission (the “SEC”) a proxy statement (the “Proxy Statement”) relating to a special meeting of Varex’s stockholders to be held to adopt the Merger Agreement, and Varex will mail the definitive Proxy Statement to its stockholders and file other documents regarding the proposed Transaction with the SEC. This communication is not a substitute for the Proxy Statement or any other document that Varex may file with the SEC in connection with the proposed Transaction. INVESTORS AND SECURITY HOLDERS OF VAREX ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE PROXY STATEMENT WHEN IT BECOMES AVAILABLE, ANY AMENDMENTS OR SUPPLEMENTS TO THE PROXY STATEMENT, AND OTHER DOCUMENTS FILED BY VAREX WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION, BECAUSE THESE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the Proxy Statement and other documents filed with the SEC by Varex through the website maintained by the SEC at www.sec.gov. Security holders will also be able to obtain free copies of the documents filed by Varex with the SEC on Varex’s website at www.vareximaging.com.

No Offer or Solicitation

This communication is for informational purposes only and not intended to and does not constitute an offer to subscribe for, buy or sell, the solicitation of an offer to subscribe for, buy or sell or an invitation to subscribe for, buy or sell any securities or the solicitation of any vote or approval in any jurisdiction pursuant to or in connection with the proposed Transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.

Cautionary Statement Regarding Forward-Looking Statements

This release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, with respect to management’s beliefs about the financial condition, results of operations and businesses of Teledyne and Varex in the future. Forward-looking statements involve risks and uncertainties, are based on the current expectations of the management of Teledyne and Varex and are subject to uncertainty and changes in circumstances. The forward-looking statements contained herein may include statements about the expected effects of Teledyne’s proposed acquisition of Varex, potential benefits to Varex’s customers and employees, the anticipated timing and scope of the proposed Transaction and anticipated synergies related to the proposed Transaction, and other strategic options. Forward-looking statements generally are accompanied by words such as “projects”, “intends”, “expects”, “anticipates”, “targets”, “estimates”, “will” and words of similar import that convey the uncertainty of future events or outcomes. All statements made in this communication that are not historical in nature should be considered forward-looking. By its nature, forward-looking information is not a guarantee of future performance or results and involves risks and uncertainties because it relates to events and depends on circumstances that will occur in the future.

Actual results could differ materially from these forward-looking statements. Many factors could change anticipated results, including the occurrence of any event, change or other circumstances that could give rise to the right of Teledyne or Varex or both to terminate the Merger Agreement; the outcome of any legal proceedings that may be instituted against Teledyne or Varex in connection with the Merger Agreement; the failure to satisfy any of the conditions to the proposed Transaction, including regulatory approvals, on a timely basis or at all; the inability to complete the acquisition and integration of Varex successfully, to retain customers and key employees and to achieve operating synergies, including the possibility that the anticipated benefits of the proposed Transaction are not realized when expected or at all, including as a result of the impact of, or problems arising from, the integration of the two companies or as a result of the strength of the economy and competitive factors in the areas where Teledyne and Varex do business; the possibility that the proposed Transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events; the parties’ ability to meet expectations regarding the timing, completion and accounting and tax treatments of the proposed Transaction; changes in relevant tax and other laws; the inability to develop and market new competitive products; inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements and the providing of estimates of financial measures, in accordance with U.S. GAAP and related standards; and operating results of Varex being lower than anticipated.

Additional factors that could cause results to differ materially from those described above can be found in Teledyne’s Annual Report on Form 10-K for the year ended December 28, 2025, and its Quarterly Reports on Form 10-Q for the periods ended March 29 and June 28, 2026, all of which are on file with the SEC and available in the “Investors” section of Teledyne’s website, www.teledyne.com, under the heading “Investor Information” and in other documents Teledyne files with the SEC, and in Varex’s Annual Report on Form 10-K for the year ended October 3, 2025, and its Quarterly Reports on Form 10-Q for the periods ended January 2 and April 3, all of which are on file with the SEC and in other documents Varex files with the SEC.

All forward-looking statements speak only as of the date they are made and are based on information available at that time. Neither Teledyne nor Varex assumes any obligation to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements were made or to reflect the occurrence of unanticipated events except as required by federal securities laws. As forward-looking statements involve significant risks and uncertainties, caution should be exercised against placing undue reliance on such statements.

Teledyne Technologies Incorporated

Varex Imaging Corporation

The post Teledyne to Acquire Varex Imaging Corporation appeared first on Varex Imaging.

Q3FY26 Summary

• Revenues $211 million
• GAAP gross margin 36% | Non-GAAP gross margin* 37%
• GAAP operating margin 11% | Non-GAAP operating margin* 12%
• GAAP net income $0.37 per diluted share | Non-GAAP net income* $0.31 per diluted share
• Cash flow from operations of $21 million

“Third-quarter product sales before the IEEPA-related customer reimbursement adjustment were approximately $217 million, reflecting strong growth in Industrial and continued expansion in cargo and vehicle inspection systems,” said Sunny Sanyal, Chief Executive Officer. “The quarter also included the recovery of tariffs that had increased our product costs in prior periods. We generated $21 million of operating cash flow and enter the fourth quarter with continued momentum.”

During the quarter, Varex received refunds totaling $17 million from U.S. Customs related to previously paid IEEPA tariffs. The Company recorded a corresponding $7 million reduction to revenues reflecting an accrual for expected customer reimbursements of previously billed IEEPA tariffs. Together, these items resulted in higher third-quarter gross profit by approximately $10 million.

Third quarter revenues were up 4% year-over-year. Third quarter Medical revenue was $134 million and Industrial revenue was $77 million. Non-GAAP gross margin increased to 37% from 34% in the prior-year quarter, and non-GAAP EPS was $0.31 compared to $0.13 in the third quarter of fiscal year 2025.

Balance Sheet & Cash Flow

Cash, cash equivalents, and marketable securities were $99 million as of the end of the third quarter, compared to $155 million at the end of fiscal year 2025. The change in cash primarily reflects the Company’s debt redemption and refinancing completed in March, as well as increased working capital associated with inventory.

Non-GAAP Financial Measures

*Please refer to “Reconciliation between GAAP and non-GAAP Financial Measures” below for a reconciliation of non-GAAP items to the comparable GAAP measures.

Cancellation of Earnings Conference Call

In light of the announced transaction with Teledyne Technologies Incorporated, and as is customary during the pendency of such a transaction, Varex has cancelled its earnings conference call for the third quarter of fiscal year 2026 previously scheduled for 3:00 p.m. Mountain Time on August 10, 2026, and will not be providing financial guidance in conjunction with its third quarter fiscal year 2026 earnings release.

About Varex

Varex Imaging Corporation is a leading innovator, designer, and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors, and other image processing solutions that are key components of X-ray imaging systems, as well as X-ray imaging systems for industrial applications. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate the company’s X-ray sources, digital detectors, connecting devices, and imaging software in their systems to detect, diagnose, protect, and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,500 people located in North America, Europe, and Asia. For more information visit www.vareximaging.com.

Forward Looking Statements

This news release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning unaudited financial results; industry or business outlook; product demand environment; and any statements using the terms “believe,” “expect,” “anticipate,” “can,” “should,” “would,” “could,” “estimate,” “may,” “intend,” and “potential,” or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company’s actual results and the outcome and timing of certain events to differ materially from those projected or management’s current expectations. While forward-looking statements are based on assumptions and analyses made by management of Varex that it believes to be reasonable under the circumstances, actual results and developments will depend on a number of risks and uncertainties which could cause actual results, performance, and financial condition to differ materially from such expectations. Such risks and uncertainties include: the ability of the parties to consummate the proposed transaction with Teledyne on anticipated terms and timing or at all, including obtaining stockholder and regulatory approvals and other conditions to the completion of the transaction; changes in import/export regulatory regimes, tariffs, trade wars, and national policies, including exemptions thereto; reduction in or loss of business of one or more of the company’s limited original equipment manufacturing customers; global, regional, and country-specific economic instability, shifting political environments, changing tax treatment, tariffs, trade wars, and other risks associated with international manufacturing, operations and sales; loss of business to, and an inability to effectively compete with, competitors; pricing pressures and other factors that could result in market erosion or loss of customers; failure to meet customers’ needs and demands; supply chain disruptions resulting in delayed product delivery, and increased costs as a result of reliance on a limited number of suppliers for certain key components; disruption of critical information systems or material breaches in the security of such systems; inability to maintain or defend intellectual property rights, and cost associated with protecting the company’s intellectual property and defending such rights and defending against infringement claims; non-compliance with regulations applicable to marketing, manufacturing, labeling, and distributing the company’s products and delays in obtaining regulatory clearances or approvals; limitations imposed by operating and financial restrictions of the company’s debt financing agreements; the financial results of the company’s equity method investments and joint ventures, and the other risks listed from time to time in the company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us in this news release speaks only as of the date on which it is made. Factors or events that could cause the company’s actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. Varex assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.

Varex has not filed its Form 10-Q for the third quarter of fiscal year 2026. All financial results described here should be considered preliminary and are subject to change to reflect any necessary adjustments or changes in accounting estimates that are identified prior to the time Varex files its Form 10-Q.

#     #     #

For Information Contact:

Sam Maheshwari

Chief Financial Officer

Varex Imaging Corporation

801.973.1574 | investors@vareximaging.com

The post VAREX ANNOUNCES FINANCIAL RESULTS FOR THIRD QUARTER FISCAL YEAR 2026 appeared first on Varex Imaging.

Photon-counting CT (PCCT) provides intrinsic spectral imaging, higher spatial resolution, and improved dose efficiency compared with energy-integrating detector CT [1-5]. Achieving diagnostic-grade PCCT requires tight control of detector linearity, spectral fidelity, and count-rate performance to limit distortion from charge sharing and pulse pileup [1,4,6,7]. The Pyxis platform integrates detector hardware and real-time corrections into a unified architecture, enabling OEMs to reduce system integration complexity and accelerate time to market (TTM).

Pyxis_PCCT_White_Paper_Technical

Pyxis_PCCT_White_Paper_Technical

Pyxis_PCCT_White_Paper_Commercial
Pyxis_PCCT_White_Paper_Commercial

The post White Paper: Pyxis™ Photon-Counting CT Detection Platform – Simplifying the Integration of Photon-Counting Computed Tomography appeared first on Varex Imaging.

Varex_MBX_White_Paper

Varex_MBX_White_Paper-1

The post Replacing Mechanical Motion in X-ray Imaging: Varex Multi-Beam X-ray (MBX) Technology appeared first on Varex Imaging.

“Eliminating Artifacts and Boosting Efficiency with Varex TrueSpectrum Imaging”

The challenge is familiar to anyone inspecting multi-material parts. A steel spring inside a polymer housing — like the everyday auto-injector pen used in the talk — produces strong beam-hardening artifacts that bury the features you need to detect and measure. The conventional fix, heavy copper beam filtration, reduces those artifacts but throws away flux: more dose, longer scans, and still some residual artifacts.

TrueSpectrum takes a different route. Using dual-energy acquisition on a photon-counting detector, it reaches cleaner interiors and surfaces from a single scan — with no physical filter in the beam.

What the talk covered

The problem: Multi-material parts create beam-hardening artifacts that block both detection and measurement in CT.

Two paths, one scan: VMI tuned for interior volume; TrueSpectrum Express (TSx) for exterior surface quality — from the same acquisition.

Breaking the trade-off: Artifact reduction without the dose, time, and flux penalty of heavy beam filtration.

What is TrueSpectrum Imaging?

TrueSpectrum is Varex Imaging’s dual-energy imaging approach, built on a photon-counting detector. It gives users two complementary paths from a single acquisition: a VMI (virtual monoenergetic imaging) route tuned for the best interior-volume quality, and TrueSpectrum Express (TSx), a streamlined route that excels at exterior surface quality — without material decomposition, calibration materials, or a separate VMI step. The result is artifact reduction and efficiency, breaking the trade-off that conventional beam filtration forces.

Download the Presentation

Varex Tube and Detector used in presentation

The post Tackling CT artifacts in multi-material parts: TrueSpectrum™ at ECNDT 2026 appeared first on Varex Imaging.

Management will participate in a fireside chat presentation on Wednesday, June 3, 2026 at 3:10 pm ET. The presentation will be webcast and can be accessed here or on Varex’s website at www.vareximaging.com/news.

About Varex

Varex Imaging Corporation is a leading innovator, designer, and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors, and other image processing solutions that are key components of X-ray imaging systems, as well as X-ray imaging systems for industrial applications. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate the company’s X-ray sources, digital detectors, connecting devices, and imaging software in their systems to detect, diagnose, protect, and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,450 people located in North America, Europe, and Asia. For more information visit vareximaging.com.

For Information Contact:

Sam Maheshwari

Chief Financial Officer

Varex Imaging Corporation

801.973.1574 | investors@vareximaging.com

The post VAREX TO PRESENT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE appeared first on Varex Imaging.

The post The GigaCT: Advancing Photon-Counting CT for Next-Generation Spectral Imaging appeared first on Varex Imaging.

Q2FY26 Summary

• Revenues $216 million
• GAAP gross margin 34% | Non-GAAP gross margin* 34%
• GAAP operating margin 7% | Non-GAAP operating margin* 9%
• GAAP net loss $0.19 per diluted share | Non-GAAP net income* $0.21 per diluted share
• Cash outflows from operations of $2 million

“Demand remained solid in the second quarter, with continued momentum across both our Medical and Industrial businesses driven by global CT, cargo systems and photon counting detectors,” said Sunny Sanyal, Chief Executive Officer. Sanyal added, “As we move into the second half of fiscal 2026, we are encouraged by favorable demand trends across both Medical and Industrial segments. We believe these dynamics position us well to grow revenue year-over-year in the second half of fiscal 2026.”

Varex’s second quarter revenue of $216 million was up 1% year-over-year. Medical segment revenue was $156 million, while Industrial segment revenue was $60 million. Non-GAAP gross margin was 34% in the quarter compared to 36% in the second quarter of fiscal year 2025, and non-GAAP EPS decreased to $0.21 in the quarter from $0.31 in the second quarter of fiscal year 2025.

Balance Sheet & Cash Flow

Cash outflows from operations was $2 million in the second quarter of fiscal year 2026. Cash, cash equivalents, and marketable securities was $88 million as of the end of the second quarter, compared to $155 million at the end of fiscal year 2025. The change in cash primarily reflects the Company’s debt redemption and refinancing completed in March, as well as increased working capital associated with inventory to support anticipated demand and future shipments.

Outlook

For the second half of fiscal 2026, revenue is expected to be up approximately 3% compared to the second half of fiscal 2025. As a result, full fiscal year 2026 revenue is expected to be in the range of $860 million to $880 million and non-GAAP EPS to be in the range of $0.80 to $1.00.

Guidance for the third quarter of fiscal year 2026 is as follows:

• Revenues are expected to be between $210million and $225 million
• Non-GAAP net earnings per diluted share is expected to be between $0.15 and $0.30

While the Company has applied for tariff refunds, no International Emergency Economic Powers Act (IEEPA) tariff refund is assumed in guidance.

Guidance for the company’s net earnings per diluted share is provided on a non-GAAP basis only. This non-GAAP financial measure is forward-looking, and the company is unable to provide a meaningful or accurate reconciliation to a GAAP forecast of net earnings per diluted share without unreasonable effort due to certain of these reconciling items being uncertain, out of its control, and the amount and timing of these items being unable to be reasonably predicted. The actual amounts of such reconciling items could have a significant impact on the company’s GAAP net income (loss) per diluted share.

Non-GAAP Financial Measures

*Please refer to “Reconciliation between GAAP and non-GAAP Financial Measures” below for a reconciliation of non-GAAP items to the comparable GAAP measures.

Conference Call Information

Varex will conduct its earnings conference call for the second quarter of fiscal year 2026 today at 3:00 p.m. Mountain Time. The conference call, including a supplemental slide presentation, will be webcast live and can be accessed at Varex’s website at www.vareximaging.com/investor-relations. Access will also be available by dialing 877-524-8416 from anywhere in the U.S. or by dialing 412-902-1028 from non-U.S. locations. The webcast and supplemental slide presentation will be archived on Varex’s website at www.vareximaging.com/financial-reports. A replay of the call will be available from today through May 21^st at 877-660-6853 from anywhere in the U.S. or 201-612-7415 from non-U.S. locations. The replay access code is 13760146. The listen-only webcast link is: https://event.choruscall.com/mediaframe/webcast.html?webcastid=yalsKXji

About Varex

Varex Imaging Corporation is a leading innovator, designer, and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors, and other image processing solutions that are key components of X-ray imaging systems, as well as X-ray imaging systems for industrial applications. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate the company’s X-ray sources, digital detectors, connecting devices, and imaging software in their systems to detect, diagnose, protect, and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,450 people located in North America, Europe, and Asia. For more information visit www.vareximaging.com.

Forward Looking Statements

This news release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning unaudited financial results; revenue and earnings guidance; industry or business outlook; product demand environment; expected future financial results or performance; and any statements using the terms “believe,” “expect,” “anticipate,” “can,” “should,” “would,” “could,” “estimate,” “may,” “intend,” and “potential,” or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company’s actual results and the outcome and timing of certain events to differ materially from those projected or management’s current expectations. While forward-looking statements are based on assumptions and analyses made by management of Varex that it believes to be reasonable under the circumstances, actual results and developments will depend on a number of risks and uncertainties which could cause actual results, performance, and financial condition to differ materially from such expectations. Such risks and uncertainties include: changes in import/export regulatory regimes, tariffs, trade wars, and national policies, including exemptions thereto; reduction in or loss of business of one or more of the company’s limited original equipment manufacturing customers; global, regional, and country-specific economic instability, shifting political environments, changing tax treatment, tariffs, trade wars, and other risks associated with international manufacturing, operations and sales; loss of business to, and an inability to effectively compete with, competitors; pricing pressures and other factors that could result in market erosion or loss of customers; failure to meet customers’ needs and demands; supply chain disruptions resulting in delayed product delivery, and increased costs as a result of reliance on a limited number of suppliers for certain key components; disruption of critical information systems or material breaches in the security of such systems; inability to maintain or defend intellectual property rights, and cost associated with protecting the company’s intellectual property and defending such rights and defending against infringement claims; non-compliance with regulations applicable to marketing, manufacturing, labeling, and distributing the company’s products and delays in obtaining regulatory clearances or approvals; limitations imposed by operating and financial restrictions of the company’s debt financing agreements; the financial results of the company’s equity method investments and joint ventures, and the other risks listed from time to time in the company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us in this news release speaks only as of the date on which it is made. Factors or events that could cause the company’s actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. Varex assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.

Varex has not filed its Form 10-Q for the second quarter of fiscal year 2026. All financial results described here should be considered preliminary and are subject to change to reflect any necessary adjustments or changes in accounting estimates that are identified prior to the time Varex files its Form 10-Q.

#     #     #

For Information Contact:

Christopher Belfiore

Director of Investor Relations

Varex Imaging Corporation

801.973.1566 | christopher.belfiore@vareximaging.com

The post VAREX ANNOUNCES FINANCIAL RESULTS FOR SECOND QUARTER FISCAL YEAR 2026 appeared first on Varex Imaging.

This call will be webcast live and can be accessed at the company’s website at www.vareximaging.com/investor-relations/. Investors can also access this conference call at 877-524-8416 from anywhere in the U.S. or 412-902-1028 from non-U.S. locations. The webcast of this call will be archived on the company’s website and a replay of the call will be available from May 7^th through May 21^st at 877-660-6853 from anywhere in the U.S. or 201-612-7415 from non-U.S. locations. The replay conference call access code is 13760146. The listen-only webcast link is: https://event.choruscall.com/mediaframe/webcast.html?webcastid=yalsKXji

About Varex

Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors and other image processing solutions that are key components of X-ray imaging systems, as well as X-ray imaging systems for industrial applications. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate the company’s X-ray sources, digital detectors, connecting devices and imaging software in their systems to detect, diagnose, protect and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,500 people located in North America, Europe, and Asia. For more information visit vareximaging.com.

#     #     #

For Information Contact:

Christopher Belfiore

Director of Investor Relations

Varex Imaging Corporation

801.973.1566 | investors@vareximaging.com

The post VAREX SCHEDULES SECOND QUARTER FISCAL YEAR 2026 EARNINGS RELEASE AND CONFERENCE CALL appeared first on Varex Imaging.

What is an X-ray tube and why is it important in medical imaging?

An X-ray tube serves as the heart of every X-ray imaging system, converting electrical energy into X-ray radiation for medical diagnosis. Without this component, doctors could not see inside the human body and identify fractures, infections, or other medical conditions.

Medical X-ray tubes function as the radiation source in diagnostic imaging equipment. They enable healthcare professionals to capture images of bones, organs, and soft tissues without invasive procedures. From routine static X-rays to complex applications in computed tomography scanners, these devices make modern medical diagnosis possible.

The importance extends beyond basic radiography. X-ray tubes power mammography systems for breast cancer screening, dental imaging for oral health assessment, and fluoroscopy for real-time, interventional medical procedures. Each application requires specific tube designs optimized for imaging needs and patient safety requirements.

How does an X-ray tube produce X-rays?

X-ray production occurs through a controlled process of electron acceleration and collision. The tube heats a filament cathode to release electrons, accelerates them across a vacuum using high voltage, and directs them toward a metal target where X-rays form upon impact.

The process begins when electrical current heats the cathode filament, typically made of tungsten. This heating causes thermionic emission, releasing free electrons into the vacuum chamber. The number of electrons released determines the X-ray beam intensity.

High voltage, usually between 40 and 150 kilovolts, accelerates these electrons toward the anode target at tremendous speeds. When the high-energy electrons strike the target material, they interact with the metal’s atoms. This interaction converts approximately 1% of the energy from all the electrons into X-rays, while the remaining 99% becomes heat.

Two types of X-rays form during this process: characteristic X-rays from electron interactions with electrons of the target’s inner atomic shells, and bremsstrahlung radiation from electron deceleration near atomic nuclei. The combination creates the X-ray spectrum used for medical imaging.

What are the main components inside an X-ray tube?

An X-ray tube contains four primary components: cathode assembly, rotating target assembly or anode, vacuum chamber, and protective housing. Each component plays a specific role in X-ray generation and safe operation.

The cathode assembly includes the filament and focusing cup. The tungsten filament produces electrons when heated, while the focusing cup shapes and directs the electron beam toward the target. Most modern tubes use dual filaments for different focal spot sizes.

The anode serves as the target for electron bombardment. Rotating anodes distribute heat across a larger surface area, allowing higher power operation than stationary anodes. The target material, typically tungsten or tungsten–rhenium alloy, provides optimal X-ray production characteristics owing to its high-density melting temperature.

The vacuum chamber eliminates air molecules that would interfere with electron travel. The chamber, made of glass or metal, maintains the vacuum while allowing X-rays to exit through designated windows. The protective housing shields operators from radiation and provides electrical insulation.

Additional components include the rotor and stator assembly for anode rotation, high-voltage connections, and cooling systems. These elements work together to ensure reliable X-ray production and safe operation.

Why do X-ray tubes need to be replaced and how long do they last?

X-ray tubes require replacement due to gradual wear from heat stress, target and filament material erosion, and vacuum degradation. Most diagnostic X-ray tubes last 100,000 to 200,000 exposures, or 3–7 years, depending on usage patterns and maintenance quality.

Heat damage represents the primary cause of tube failure. Each X-ray exposure generates significant heat at the anode target, causing thermal stress and eventual cracking. Heavy usage, inadequate cooling, or excessive technique factors accelerate this wear process. Another primary contributor to X-ray tube failure can be the evaporation of the tungsten filament.

Vacuum loss occurs when the tube envelope develops microscopic leaks or when getter materials become saturated. Air molecules entering the vacuum interfere with electron flow, causing arcing and unstable X-ray output. Filament degradation also reduces electron emission over time.

Signs indicating tube replacement include increased exposure times, reduced X-ray output, image quality deterioration, unusual noises during operation, or frequent error messages. Regular maintenance and proper technique selection help maximize tube lifespan.

How Varex Imaging helps with X-ray tube technology

We provide advanced X-ray tube solutions that help OEM manufacturers develop superior imaging systems. Our tubes deliver reliable performance, extended lifespan, and innovative features that enable manufacturers to differentiate their products in competitive markets.

Our comprehensive X-ray tube portfolio includes:

• Rotating anode tubes for high-power diagnostic applications
• Stationary anode tubes for lower-power imaging needs
• Specialized mammography tubes for breast imaging systems
• CT tubes designed for computed tomography scanners
• Custom tube solutions for unique OEM requirements

We support OEM partners with engineering expertise, technical consultation, and rapid prototyping capabilities. Our global manufacturing facilities ensure consistent supply chain reliability, while our quality systems meet international medical device standards.

Partner with us to access innovative X-ray tube technology that helps you deliver superior imaging systems to healthcare providers worldwide. Contact our team to discuss your specific tube requirements and learn how we can support your next-generation imaging system development.

The post How does an X-ray tube work? appeared first on Varex Imaging.